 Home > Active Ingredient News > Antitumor Therapy > JAMA Netw Open: 25-year survival assessment of ER+/HER2- female breast cancer patients with or without tamoxifen: a secondary analysis of the Stockholm tamoxifen (STO-3) study

JAMA Netw Open: 25-year survival assessment of ER+/HER2- female breast cancer patients with or without tamoxifen: a secondary analysis of the Stockholm tamoxifen (STO-3) study

 Last Update: 2021-08-01
 Source: Internet
 Author: User

Tags

natural forms estrogen

1 1a 8

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Breast cancer is a common malignant tumor in women

This study is a secondary analysis of 565 female patients in the Stockholm tamoxifen (STO-3) randomized clinical study

Research Overview

The study included 565 patients with an average age of 62 years

T1a/b patients have longer long-term remote recurrence-free intervals (DRFI) than T1c and T2 patients, which are 88% (95%CI, 80%-93%) and 76% (95%CI, 70%-81%), respectively ), 63% (95%CI, 50%-73%; log-rank P <0.

Remote recurrence-free interval (DRFI) analysis

Multivariate Cox regression analysis showed that small tumors and larger tumors have a lower risk of distant recurrence (T1a/b vs T2, HR=0.

No risk of recurrence at a distance

Compared with patients who did not receive adjuvant endocrine therapy, patients with large tumors who received tamoxifen benefited more, patients with T1c (HR, 0.

Compared with patients who did not receive adjuvant endocrine therapy, patients with large tumors who received tamoxifen benefited more.

Stratified analysis of the benefit of tamoxifen or not

In summary, the study shows that for a specific patient, tumor size and tumor grade are related to the long-term survival of the patient

In summary, the study shows that for a specific patient, tumor size and tumor grade are related to the long-term survival of the patient
.
Among ER+/HER2- patients, large tumors, low-grade, and PR-positive patients can benefit from tamoxifen for long-term survival
.
The study shows that for certain patients, tumor size and tumor grade are related to the long-term survival of the patient
.
Among ER+/HER2- patients, large tumors, low-grade, and PR-positive patients can benefit from tamoxifen for long-term survival
.
The study shows that for certain patients, tumor size and tumor grade are related to the long-term survival of the patient
.
Among ER+/HER2- patients, large tumors, low-grade, and PR-positive patients can benefit from tamoxifen for long-term survival
.

Original source:

HumaDar; AnnelieJohansson; AnnaNordenskjöld; et al.
Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
JAMA Network Open .
2021;4(6):e2114904.
doi:10.
1001/jamanetworkopen.
2021.
14904.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.